» Articles » PMID: 26101151

Vitamin D Intake Associates with Insulin Resistance in Type 2 Diabetes, but Not in Latent Autoimmune Diabetes in Adults

Overview
Journal Nutr Res
Date 2015 Jun 24
PMID 26101151
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

This study aimed to evaluate the relationship between vitamin D (vitD) intake and serum concentrations and insulin secretion (assessed by C-peptide serum concentration)/insulin resistance (determined by estimated glucose disposal rate [eGDR]) in patients with latent autoimmune diabetes in adults (LADA) and type 2 diabetes (T2DM). C-peptide, serum vitD, lipid profile, insulin, glucose, and glycosylated hemoglobin (HbA1c) were assessed; vitD intake was determined; and eGDR was calculated. Groups were compared using the Student t or Mann-Whitney U test. Correlations were performed between insulin secretion, insulin resistance, and vitD, and linear regression models were adjusted for confounding variables. Of 107 patients included, age was 55.3 ± 11.84 years old, and time since diabetes diagnosis was 13.23 ± 5.96 years. There were significant intergroup differences in age, body mass index (BMI), hip measurements, glucose, and HbA1c. The correlation between vitD intake and C-peptide for the whole group was significant (r = 0.213; P = .032) as well as for vitD deficiency/sufficiency in T2DM (P = .042), whereas neither was significant in eGDR. After adjustment for age, HbA1c, disease progression, physical activity, solar exposure, sex, and BMI, vitD intake was only significant in T2DM (P = .028). In serum vitD, only the correlation between eGDR and vitD in T2DM was significant and intragroup when comparing vitD sufficiency. After adjustments, significance was lost. Patients with LADA had lower intake of vitD, poorer metabolic control, lower BMI, and younger age compared to T2DM patients. There was no association between serum vitD or vitD intake and insulin secretion when analyzed by group, although vitD intake was associated with insulin resistance in T2DM, but not LADA.

Citing Articles

Ameliorative effect of liprotide-encapsulated vitamin D3 on blood glucose, calcium homeostasis, and vitamin D level in a vitamin D and calcium deficient rat model.

Anjani G, Achmad Maulana R, Putri S, Fulyani F, Syauqy A, Afifah D Front Nutr. 2025; 12:1514179.

PMID: 39935579 PMC: 11810727. DOI: 10.3389/fnut.2025.1514179.


Vitamin D Supplementation as a Therapeutic Strategy in Autoimmune Diabetes: Insights and Implications for LADA Management.

Mourelatou N, Kounatidis D, Jude E, Rebelos E Nutrients. 2024; 16(23).

PMID: 39683465 PMC: 11643312. DOI: 10.3390/nu16234072.


Efficacy of Regimens in the Treatment of Latent Autoimmune Diabetes in Adults: A Network Meta-analysis.

Wang W, Huang F, Han C Diabetes Ther. 2023; 14(10):1723-1752.

PMID: 37584857 PMC: 10499777. DOI: 10.1007/s13300-023-01459-5.


Identification and phenotypic characterization of patients with LADA in a population of southeast Mexico.

Nolasco-Rosales G, Ramirez-Gonzalez D, Rodriguez-Sanchez E, Avila-Fernandez A, Villar-Juarez G, Gonzalez-Castro T Sci Rep. 2023; 13(1):7029.

PMID: 37120620 PMC: 10148806. DOI: 10.1038/s41598-023-34171-2.


Effect of Vitamin D deficiency treatment on thyroid function and autoimmunity markers in Hashimoto's thyroiditis: A double-blind randomized placebo-controlled clinical trial.

Vahabi Anaraki P, Aminorroaya A, Amini M, Momeni F, Feizi A, Iraj B J Res Med Sci. 2017; 22:103.

PMID: 29026419 PMC: 5629831. DOI: 10.4103/jrms.JRMS_1048_16.